{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:32:41Z","timestamp":1793039561055,"version":"4.5.0"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00849","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:24:20Z","timestamp":1590557060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":81,"title":["CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences"],"prefix":"10.3389","volume":"10","author":[{"given":"Candida","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma."},{"key":"B2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/jco.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"55ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.1200\/JCO.2019.37.15_suppl.7562","article-title":"Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"37","author":"Dean","year":"2019","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood-2019-125769","article-title":"Clinical and radiological correlates of neurotoxicity after standard of care axicabtagene ciloleucel in patients with relapsed\/refractory large B-cell lymphoma","volume":"134","author":"Strati","year":"2019","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2017.35.15_suppl.3023","article-title":"Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)","volume":"35","author":"Locke","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2019-127094","article-title":"Peak lymphocyte count after CAR T infusion is a clinically accessible test that correlates with clinical response in axicabtagene ciloleucel therapy for lymphoma","volume":"134","author":"Novo","year":"2019","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1182\/blood-2019-130815","article-title":"Identification of two CAR T-cell populations associated with complete response or progressive disease in adult lymphoma patients treated with axi-cel","volume":"134","author":"Good","year":"2019","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1182\/blood-2019-131041","article-title":"Tumor inflammation and myeloid derived suppressor cells reduce the efficacy of CD19 CAR T cell therapy in lymphoma","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","article-title":"Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)","volume":"35","author":"Galon","year":"2017","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2018-99-113644","article-title":"Analysis of CAR-T and immune cells within the tumor micro-environment of diffuse large B-cell lymphoma post CAR-T treatment by multiplex immunofluorescence","volume":"132","author":"Chen","year":"2018","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1200\/JCO.2019.37.15_suppl.7560","article-title":"Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy","volume":"37","author":"Sirous","year":"2019","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2019-132057","article-title":"Detectable circulating tumor DNA 28 days after the CD19 CAR T-cell therapy, axicabtagene ciloleucel, is associated with poor outcomes in patients with diffuse large B-cell lymphoma","volume":"134","author":"Frank","year":"2019","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2019-129015","article-title":"Circulating DNA for molecular response prediction, characterization of resistance mechanisms and quantification of CAR T-cells during axicabtagene ciloleucel therapy","volume":"134","author":"Sworder","year":"2019","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1182\/blood-2019-124694","article-title":"Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed\/refractory DLBCL: a multicenter retrospective analysis","volume":"134","author":"Kittai","year":"2019","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma","volume":"132","author":"Sano","year":"2018","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood-2019-125162","article-title":"Impact and safety of chimeric antigen receptor T cell therapy in vulnerable older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"134","author":"Lin","year":"2019","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood-2019-124364","article-title":"Medicare patients receiving chimeric antigen receptor T-cell therapy for non-hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs","volume":"134","author":"Kilgore","year":"2019","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood-2019-127372","article-title":"Real-world analysis of adverse events associated with CAR T-cell therapy among adults age \u226565 years","volume":"134","author":"Zettler","year":"2019","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood-2019-131168","article-title":"Characteristics and outcomes of patients who did not develop CRS after axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma: results from the US lymphoma CAR-T consortium","volume":"134","author":"Jacobs","year":"2019","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2019-126148","article-title":"Fever characteristics associated with toxicity and outcome after anti-CD19 CAR T-cell therapy for aggressive lymphoma","volume":"134","author":"Hashmi","year":"2019","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1182\/blood-2018-99-115393","article-title":"Sublingual microcirculatory imaging as a novel tool to monitor for cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"132","author":"Deitchman","year":"2018","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1182\/blood-2019-125794","article-title":"Increased cortical glycolysis following CD19 CART therapy: a radiographic surrogate for an altered blood-brain barrier","volume":"134","author":"Bukhari","year":"2019","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2019-125400","article-title":"Immune effector cell-associated neurotoxicity syndrome (ICANS) after CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) for large B-cell lymphoma: predictive biomarkers and clinical outcomes","volume":"134","author":"Holtzman","year":"2019","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/blood-2018-99-116539","article-title":"Prediction of CAR T-related toxicities in R\/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements","volume":"132","author":"Faramand","year":"2018","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1182\/blood-2019-127305","article-title":"The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2019-126208","article-title":"Easix and modified-easix are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells","volume":"134","author":"Pennisi","year":"2019","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory large B cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1182\/blood-2019-122195","article-title":"Granulocyte colony-stimulating factor (G-CSF) interactions with chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma","volume":"134","author":"Gaut","year":"2019","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood-2019-131306","article-title":"Thirty-day transfusion and G-CSF requirement after CD19 CAR T infusion","volume":"134","author":"Hsu","year":"2019","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e14019","DOI":"10.1200\/JCO.2019.37.15_suppl.e14019","article-title":"Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL)","volume":"37","author":"Logue","year":"2019","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"","journal-title":"Leuk Lymphoma."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1200\/JCO.2019.37.15_suppl.7545","article-title":"Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma","volume":"37","author":"Strati","year":"2019","journal-title":"J Clin Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2019.37.15_suppl.2540","article-title":"Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR -T) associated non-relapse mortality (CART-NRM) from FAERS","volume":"37","author":"Anand","year":"2019","journal-title":"J Clin Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood-2019-131077","article-title":"Comparative review of 30 day non-relapse mortality (NRM) in B-cell lymphomas associated with anti-CD19 chimeric antigen receptor T-cells (CAR-T) from FDA database, clinical studies, and MD anderson","volume":"134","author":"Burns","year":"2019","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1182\/blood-2018-99-112254","article-title":"Analysis of hospitalization and readmissions after CAR T cell therapy","author":"O'Donnell","year":"2018","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1182\/blood-2019-122587","article-title":"Economic burden of neurologic toxicities associated with treating relapsed refractory diffuse large B-cell lymphoma in the United States","volume":"134","author":"Broder","year":"2019","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e190035","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2019-127490","article-title":"A Multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood-2018-99-111711","article-title":"Patient-reported and neurocognitive outcomes in patients treated with axicabtagene ciloleucel","volume":"132","author":"Jim","year":"2018","journal-title":"Blood."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/blood-2019-129593","article-title":"Neurological adverse events following CAR-T cell therapy: a real-world analysis of adult patients treated with axicabtagene ciloleucel or tisagenlecleucel","volume":"134","author":"Gajra","year":"2019","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2019-124177","article-title":"Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England","volume":"134","author":"Kuhnl","year":"2019","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1182\/blood-2019-127087","article-title":"Outcomes and factors impacting use of axicabtagene ciloleucel in refractory and relapsed large B-cell lymphoma: an intent-to-treat analysis","volume":"134","author":"Mian","year":"2019","journal-title":"Blood."},{"key":"B55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2019-129624","article-title":"Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US lymphoma CAR-T consortium","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1182\/blood-2019-131399","article-title":"A characterization of bridging therapies leading up to commercial CAR T-cell therapy","volume":"134","author":"Dwivedy Nasta","year":"2019","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2019-129421","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse\/refractory diffuse large B- cell lymphoma in real world experience","volume":"134","author":"Paillassa","year":"2019","journal-title":"Blood."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1182\/blood-2019-131449","article-title":"MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy","volume":"134","author":"Imber","year":"2019","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2019-131499","article-title":"Radiation therapy can be an effective bridging strategy prior to axicabtagene ciloleucel therapy for relapsed\/refractory large B-cell lymphoma","volume":"134","author":"Pinnix","year":"2019","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1200\/JCO.2019.37.15_suppl.7517","article-title":"Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US Lymphoma CAR-T Consortium","volume":"37","author":"Spiegel","year":"2019","journal-title":"J Clin Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood-2018-99-115252","article-title":"Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of juliet, a global pivotal phase 2 trial of tisagenlecleucel","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1182\/blood-2019-129107","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the juliet trial","volume":"134","author":"Westin","year":"2019","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1182\/blood-2019-124492","article-title":"Correlation of bridging and lymphodepleting chemotherapy with clinical outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma treated with tisagenlecleucel","volume":"134","author":"Andreadis","year":"2019","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2018-99-116385","article-title":"Evaluation of in vivo CAR transgene levels in relapsed\/refractory pediatric and young adult ALL and adult DLBCL tisagenlecleucel-treated patients","volume":"132","author":"Awasthi","year":"2018","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/blood-2018-99-115094","article-title":"Safety and efficacy of tisagenlecleucel treatment in patients with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) and no evidence of active disease following bridging chemotherapy in the JULIET trial","volume":"132","author":"Bishop","year":"2018","journal-title":"Blood."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv."},{"key":"B69","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2019-128302","article-title":"Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL)","volume":"134","author":"Bachanova","year":"2019","journal-title":"Blood."},{"key":"B70","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2019-131078","article-title":"Outcomes in aggressive B-cell non-hodgkin lymphomas with anti-CD19 CAR T-cell (CTL019) products not meeting commercial release specifications","volume":"134","author":"Chong","year":"2019","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2018-99-113052","article-title":"Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel on the JULIET study","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood."},{"key":"B73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1182\/blood-2018-99-118595","article-title":"Grading of neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) receiving tisagenlecleucel treatment in the JULIET study","volume":"132","author":"Maziarz","year":"2018","journal-title":"Blood."},{"key":"B75","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1016\/j.clml.2019.07.158","article-title":"Correlative analyses of cytokine release syndrome and neurological events in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"19","author":"Bachanova","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B76","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the center for international blood & marrow transplant research (CIBMTR) cellular therapy (CT) registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2019-125801","article-title":"Statistical learning approaches for predicting lisocabtagene maraleucel (liso-cel) drug product composition from donor-selected material composition","volume":"134","author":"Jiang","year":"2019","journal-title":"Blood."},{"key":"B78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/blood-2019-127150","article-title":"Lisocabtagene maraleucel (liso-cel) manufacturing process control and robustness across CD19+ hematological malignancies","volume":"134","author":"Teoh","year":"2019","journal-title":"Blood."},{"key":"B79","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood."},{"key":"B81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/blood-2019-127145","article-title":"Impact of lisocabtagene maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients (pts) with relapsed\/refractory (R\/R) aggressive B cell non-hodgkin lymphoma (NHL): transcend NHL 001","volume":"134","author":"Patrick","year":"2019","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2019-127658","article-title":"Lisocabtagene maraleucel (liso-cel) for treatment of second-line transplant noneligible (TNE) relapsed\/refractory (R\/R) aggressive non-hodgkin lymphoma (NHL): initial results from the PILOT study","volume":"134","author":"Sehgal","year":"2019","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2019-127683","article-title":"Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed\/refractory (R\/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response","volume":"134","author":"Reiss","year":"2019","journal-title":"Blood."},{"key":"B84","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.1200\/JCO.2019.37.15_suppl.7515","article-title":"Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: initial results from TRANSCEND NHL 001","volume":"37","author":"Abramson","year":"2019","journal-title":"J Clin Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1182\/blood-2019-127566","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed\/refractory (R\/R) B cell non-hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, outreach, PILOT","volume":"134","author":"Bachier","year":"2019","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2018-99-112214","article-title":"Estimation of the resource utilization and costs of cytokine release syndrome observed in the transcend-NHL clinical trial: a Micro-Costing study","volume":"132","author":"Siddiqi","year":"2018","journal-title":"Blood."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1182\/blood-2018-99-119387","article-title":"TRANSCEND: lisocabtagene maraleucel (liso-cel; JCAR017) healthcare resource utilization in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL)","volume":"132","author":"Palomba","year":"2018","journal-title":"Blood."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/jco.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hon.96_2629","article-title":"CD19-directed CAR T cell therapy (CTL019) for relapsed\/refractory diffuse large B-cell and follicular lymphomas: four year outcomes","volume":"37","author":"Chong","year":"2019","journal-title":"Hematol Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood."},{"key":"B94","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.111_2630","article-title":"Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene meraleucel in TRANSCEND NHL 001","volume":"37","author":"Wang","year":"2019","journal-title":"Hematol Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.2016.34.15_suppl.3009","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL","volume":"34","author":"Porter","year":"2016","journal-title":"J Clin Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2016.34.15_suppl.102","article-title":"Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells","volume":"34","author":"Turtle","year":"2016","journal-title":"J Clin Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/jco.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2019-127603","article-title":"Rapid undetectable MRD (uMRD) responses in patients with relapsed\/refractory (R\/R) Chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product: updated results from transcend CLL 004, a phase 1\/2 study including patients with high-risk disease previously treated with ibrutinib","volume":"134","author":"Siddiqi","year":"2019","journal-title":"Blood."},{"key":"B101","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood."},{"key":"B102","doi-asserted-by":"publisher","first-page":"122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL","volume":"5","author":"Geyer","year":"2019","journal-title":"JCI Insight."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia."},{"key":"B105","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/jci89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood-2019-125617","article-title":"Ibrutinib treatment mitigates phenotypic alterations of non-neoplastic immune cell compartments in chronic lymphocytic leukemia","volume":"134","author":"Griggio","year":"2019","journal-title":"Blood."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1182\/blood.V128.22.3231.3231","article-title":"Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia","volume":"128","author":"Qin","year":"2016","journal-title":"Blood."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood."},{"key":"B112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.V128.22.58.58","article-title":"Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed\/refractory CLL","volume":"128","author":"Geyer","year":"2016","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood."},{"key":"B114","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2018-99-111061","article-title":"Comparison of efficacy toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and\/or refractory CLL","volume":"132","author":"Gauthier","year":"2018","journal-title":"Blood."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1182\/blood-2019-127751","article-title":"Clinical response in relapsed\/refractory (R\/R) B-NHL treated with the CD19-directed CAR T-cell product JWCAR029","volume":"134","author":"Ying","year":"2019","journal-title":"Blood."},{"key":"B116","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell."},{"key":"B118","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.ccr-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2019-125423","article-title":"Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients","volume":"134","author":"Schubert","year":"2019","journal-title":"Blood."},{"key":"B122","doi-asserted-by":"publisher","first-page":"e026644","DOI":"10.1136\/bmjopen-2018-026644","article-title":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I\/II clinical trial protocol","volume":"9","author":"Schubert","year":"2019","journal-title":"BMJ Open."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood."},{"key":"B125","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/cji.0000000000000199","article-title":"Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions","volume":"41","author":"Lee","year":"2018","journal-title":"J Immunother."},{"key":"B126","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/jci86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest."},{"key":"B129","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood."},{"key":"B130","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.cir-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/jci87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest."},{"key":"B132","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.cir-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.2019.37.15_suppl.2510","article-title":"Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood."},{"key":"B136","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood."},{"key":"B137","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1182\/blood-2019-129120","article-title":"Portia: a phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"134","author":"Jaeger","year":"2019","journal-title":"Blood."},{"key":"B138","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from Zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/blood-2018-99-116745","article-title":"Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed\/refractory aggressive B-cell non-hodgkin lymphoma","volume":"132","author":"Hirayama","year":"2018","journal-title":"Blood."},{"key":"B140","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hon.128_2629","article-title":"Safety of lisocabtagene maraleucel given with durvalumab in patients with relapsed\/refractory aggressive B-cell non Hodgkin lymphoma: first results from the PLATFORM study","volume":"37","author":"Siddiqi","year":"2019","journal-title":"Hematol Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e1115940","DOI":"10.1080\/2162402x.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Otahal","year":"2016","journal-title":"Oncoimmunology."},{"key":"B142","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.ccr-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.mct-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-019-0155-8","article-title":"Gut microbiome and CAR-T therapy","volume":"8","author":"Abid","year":"2019","journal-title":"Exp Hematol Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia."},{"key":"B146","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"key":"B148","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hon.124_2629","article-title":"Phase I clinical trial of CD19-targeted 19-28Z\/4-1BBL \u201carmored\u201d CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation","volume":"37","author":"Batlevi","year":"2019","journal-title":"Hematol Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.can-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"B151","doi-asserted-by":"publisher","first-page":"7557","DOI":"10.1200\/JCO.2019.37.15_suppl.7557","article-title":"A phase I trial using CD19 CAR-T expressing PD-1\/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma","volume":"37","author":"Liu","year":"2019","journal-title":"J Clin Oncol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11899-017-0417-7","article-title":"Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer","volume":"12","author":"Singh","year":"2017","journal-title":"Curr Hematol Malig Rep."},{"key":"B153","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood."},{"key":"B155","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1182\/blood-2019-128203","article-title":"Initial findings of the phase 1 trial of PBCAR0191, a CD19 targeted allogeneic CAR-T cell therapy","volume":"134","author":"Jacobson","year":"2019","journal-title":"Blood."},{"key":"B156","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia."},{"key":"B157","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00849\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:24:24Z","timestamp":1590557064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00849\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":157,"alternative-id":["10.3389\/fonc.2020.00849"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00849","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"article-number":"849"}}